The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | Preliminary safety and efficacy of PBCAR0191 in R/R CD19+ NHL
Bijal Shah, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses preliminary safety and efficacy findings from a Phase I trial (NCT03666000) of PBCAR0191 in relapsed/refractory CD19+ non-Hodgkin lymphoma (NHL). Dr Shah gives an overview of the trial, highlighting novel approaches to chimeric antigen receptor (CAR) T-cell manufacturing. Dr Shah discusses data from patients who underwent intensified lymphodepletion with increased doses of cytarabine and cyclophosphamide before receiving PBCAR0191. This cohort reported a complete response rate of 71% at 28 days of follow-up. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Bijal Shah, MD, has received research funding from Kite/Gilead and Jazz Pharmaceuticals; has participated in an advisory role with Kite/Gilead, BMS/Celgene, Novartis, Precision Biomedicines, Adaptive, Jazz Pharma, Servier, AstraZeneca and Beigene.
